The Impact of Individual Human Immunodeficiency Virus Type 1 Protease Mutations on Drug Susceptibility Is Highly Influenced by Complex Interactions with the Background Protease Sequence
- 15 September 2009
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 83 (18) , 9512-9520
- https://doi.org/10.1128/jvi.00291-09
Abstract
The requirement for multiple mutations for protease inhibitor (PI) resistance necessitates a better understanding of the molecular basis of resistance development. The novel bioinformatics resistance determination approach presented here elaborates on genetic profiles observed in clinical human immunodeficiency virus type 1 (HIV-1) isolates. Synthetic protease sequences were cloned in a wild-type HIV-1 background to generate a large number of close variants, covering 69 mutation clusters between multi-PI-resistant viruses and their corresponding genetically closely related, but PI-susceptible, counterparts. The vast number of mutants generated facilitates a profound and broad analysis of the influence of the background on the effect of individual PI resistance-associated mutations (PI-RAMs) on PI susceptibility. Within a set of viruses, all PI-RAMs that differed between susceptible and resistant viruses were varied while maintaining the background sequence from the resistant virus. The PI darunavir was used to evaluate PI susceptibility. Single sets allowed delineation of the impact of individual mutations on PI susceptibility, as well as the influence of PI-RAMs on one another. Comparing across sets, it could be inferred how the background influenced the interaction between two mutations, in some cases even changing antagonistic relationships into synergistic ones or vice versa. The approach elaborates on patient data and demonstrates how the specific mutational background greatly influences the impact of individual mutations on PI susceptibility in clinical patterns.Keywords
This publication has 17 references indexed in Scilit:
- Resistance Profile of Darunavir: Combined 24-Week Results from the POWER TrialsAIDS Research and Human Retroviruses, 2008
- Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of ActionJournal of Virology, 2006
- Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistanceCurrent Medical Research and Opinion, 2006
- HIV/AIDS epidemiology, pathogenesis, prevention, and treatmentThe Lancet, 2006
- TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2005
- Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2005
- 'Working at the margins' or 'leading from behind'?: a Canadian study of hospital-community collaborationHealth & Social Care in the Community, 2005
- Discovery and Selection of TMC114, a Next Generation HIV-1 Protease InhibitorJournal of Medicinal Chemistry, 2004
- HIV Drug ResistanceNew England Journal of Medicine, 2004
- Evaluation of an early intervention Tier 2 child and adolescent mental health serviceHealth & Social Care in the Community, 2004